Standard BioTools Form 4: Fenel Eloi Adds Equity via RSUs and Options

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) has reported insider equity awards to Director Fenel M. Eloi on Form 4 dated 06/24/2025. On 06/20/2025 Eloi received 94,592 Restricted Stock Units (RSUs) valued at $0 per unit and 125,660 non-qualified stock options with an exercise price of $1.05 per share. The RSUs vest in full on the earlier of 20 June 2026 or one day before the next annual meeting, while the options vest in twelve equal monthly tranches beginning 20 July 2025 and expire 20 June 2035.

After these grants, Eloi’s direct holdings increase to 236,183 common shares and 125,660 options. The transaction code “A” indicates the shares and options were awarded by the company rather than purchased on the open market. No Rule 10b5-1 trading plan was noted, and the filing concerns routine director compensation rather than open-market buying or selling.

Insights

Financial Analyst

TL;DR: Routine equity awards; minimal dilution, neutral signal for LAB investors.

The Form 4 discloses standard annual compensation: 94.6k RSUs plus 125.7k options at $1.05. The combined potential share issuance is immaterial relative to LAB’s multi-million share float, so dilution risk is negligible. Because the awards were not open-market purchases, they do not indicate incremental insider conviction in the stock. Overall impact on valuation or near-term trading dynamics is neutral.

Corporate Governance Expert

TL;DR: Grants align director incentives; governance practice appears standard.

Equity-based compensation aligns Eloi’s interests with shareholders by tying value to share price performance through RSUs and time-vested options. Vesting schedules require a minimum one-year service commitment, supporting board stability. There is no indication of preferential pricing or accelerated vesting that might raise governance concerns. As such, the filing reflects normal, well-structured board remuneration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ELOI FENEL M

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		94,592(1)	A	$0	236,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.05	06/20/2025		A		125,660		(2)	06/20/2035	Common Stock	125,660	$0	125,660	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Fenel M. Eloi by Tomone Tanaka, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs did Director Fenel M. Eloi receive from Standard BioTools (LAB)?

Eloi was granted 94,592 Restricted Stock Units on 06/20/2025.

When do the RSUs granted to LAB Director Eloi vest?

The RSUs vest in full on 20 June 2026 or one day before the next annual shareholder meeting, whichever occurs first.

What are the key terms of the stock options awarded to Eloi?

He received 125,660 options at an $1.05 exercise price; they vest monthly over 12 months starting 20 July 2025 and expire 20 June 2035.

What is Eloi’s total direct share ownership after the Form 4 transactions?

Following the grants, Eloi directly owns 236,183 common shares plus 125,660 vested/unvested options.

Was a Rule 10b5-1 trading plan involved in these transactions?

No. The Form 4 does not indicate that the awards were made under a Rule 10b5-1 plan.